ArticleFrontiers in immunology2025
The role of vitamin D deficiency and modifiable risk factors in patients with Crohn's disease.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Vitamin D insufficiency is usually seen in Crohn's disease (CD). Our study aims to determine the risk factors for vitamin D insufficiency in CD patients. Methods: Between May 2021 and December 2023, we enrolled 102 CD patients and 100 healthy people in our hospital who were eligible for the study. Changes in vitamin D levels were also analyzed. CD patients were divided into active and clinical remission, and further changes in micronutrient and vitamin D levels were analyzed. Lastly, risk factor analysis was conducted using univariate, multivariate, and LASSO regression analysis models. Results: The average age of CD patients was 38.91 ± 3.31 years, whereas the average age of the healthy people was 38.64 ± 2.26 years. Vitamin D levels were significantly lower in CD patients than in healthy controls (19.62 ± 2.68 vs. 22.68 ± 4.61), especially for patients with active CD. In 11 patients treated with vedolizumab, compared to the pre-treatment Vedolizumab group, vitamin D levels improved more dramatically post-Vedolizumab therapy. According to univariate analysis, Age (OR: 0.95, 95% CI 0.26-1.33, p=0.01), sex (OR: 0.26, 95% CI 0.25-0.99, p=0.03), recent biologics (OR: 0.54, 95% CI 0.44-1.25, p=0.02), iron (OR: 0.89, 95% CI 0.72-1.62, p=0.02), and total 25-OH vitamin D (OR: 1.25, 95% CI 1.02-1.99, p=0.02) did significantly differ between patients with and without vitamin D deficiency. After controlling for several variables, multivariate analysis revealed that a lower odds ratio was linked to increasing age at diagnosis (OR: 0.12, 95% CI 0.03-0.85, p=0.02), sex (OR: 0.58, 95% CI 0.44-0.95, p=0.01), iron (OR: 0.44, 95% CI 0.11-0.62, p=0.01), and 25-OH vitamin D total (OR: 0.48, 95% CI 0.25-0.95, p=0.03). In addition, Age, time since illness onset, and 25-OH vitamin D were found to be helpful indicators for CD patients using LASSO regression. Conclusion: According to this study, vitamin D insufficiency was often linked to CD patients with active status and pre-treatment Vedolizumab. Furthermore, Age, time since illness onset, and 25-OH vitamin D were found to be significant risk factors for CD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.